Drug Interactions between DurAct and Ergamisol
This report displays the potential drug interactions for the following 2 drugs:
- DurAct (bromfenac)
- Ergamisol (levamisole)
Interactions between your drugs
No interactions were found between DurAct and Ergamisol. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
DurAct
A total of 370 drugs are known to interact with DurAct.
- Duract is in the drug class Nonsteroidal anti-inflammatory drugs.
Ergamisol
A total of 179 drugs are known to interact with Ergamisol.
- Ergamisol is in the drug class miscellaneous antineoplastics.
- Ergamisol is used to treat the following conditions:
Drug and food interactions
bromfenac food
Applies to: DurAct (bromfenac)
ADJUST DOSE: In-vivo studies have demonstrated that the absorption of bromfenac is greatly reduced if the drug is taken within three and one-half hours following a high fat meal. The concomitant administration of a high fat meal has led to a 75% reduction in peak plasma concentrations and a 60% reduction in total area under the curve. The mechanism has not been described.
MANAGEMENT: An increased dosage of bromfenac (from 25 to 50 mg) may be needed if a high fat meal is consumed. The clinician may want to warn the patient about subtherapeutic analgesic effects if high fat meals are regularly consumed.
References (1)
- "Product Information. DurAct (bromfenac)." Wyeth-Ayerst Laboratories
levamisole food
Applies to: Ergamisol (levamisole)
GENERALLY AVOID: Case histories have suggested that levamisole is associated with some side effects (including headache, fever, shivers, and dizziness) that suggest an disulfiram-like interaction with alcohol. These side effects could be alleviated by total abstinence from alcohol. No mechanism has been established for this interaction.
MANAGEMENT: Patients receiving levamisole should avoid alcohol.
References (3)
- (2001) "Product Information. Ergamisol (levamisole)." Janssen Pharmaceuticals
- Renoux G (1980) "The general immunopharmacology of levamisole." Drugs, 19, p. 89-99
- Renoux G (1978) "Modulation of immunity by levamisole." Pharmacol Ther [B], 2, p. 397-422
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.